表皮生长因子受体酪氨酸激酶抑制剂治疗老年晚期非小细胞肺癌临床分析  

Clinical Analysis of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Elderly Patients with Non-small-cell Lung Cancer

作　　者：农靖颖[1] 靳海龙[1] 王敬慧[1] 杨新杰[1] 孙怡芬[1] 张新勇[1] 吴羽华[1] 李曦[1] 张卉[1] 秦娜[1] 张权[1] 张树才[1] 

机构地区：[1]首都医科大学附属北京胸科医院肿瘤科,北京101149

出　　处：《结核病与胸部肿瘤》2011年第3期176-180,共5页Tuberculosis and Thoracic Tumor

摘　　要：目的评价表皮生长因子酪氨酸激酶抑制剂（EGFR—TKI）对老年晚期非小细胞肺癌（NSCLC）的疗效、生存及安全性，并探讨影响因素。方法对2006年2月至2010年9月我院收治的70例年龄≥65岁接受厄洛替尼／吉非替尼治疗的晚期非小细胞肺癌患者的疗效、生存情况及影响因素进行分析总结，并评价药物安全性。结果总有效率31．4％，疾病控制率843％，中位PFS8．0个月，中位OS13．5个月，1年生存率54．3％。卡方检验显示，女性患者的RR、DCR优于男性，非吸烟、PS〈2患者的DCR优于吸烟、PS≥2患者，统计学均有显著性差异。非吸烟和PS〈2患者预后好，是影响生存的独立因素。毒副反应主要为轻度皮疹及腹泻。结论EGFR—TKI治疗老年晚期NSCLC有效，安全性好，吸烟及PS评分是生存的独立预测因素。Objective To evaluate the outcomes of EGFR-TKI for elderly patients with non-small cell lung cancer and to investigate the association of clinical characteristics with the efficacy and survival. Method The efficacy, survival, clinical characteristics and toxicities were retrospectively analyzed in 70 patients with advanced-NSCLC aged 65 years or older who received erlotinib or gefitinib between February 2006 and September 2010, Results The overall response rate was 31.4% and the disease control rate was 84.3 %. The median progression-free survival time was 8.0 months and median survival time was 13.5 months respectively, l-year survival rate was 54.3%. RR and DCR in female patients was superior to male, DCR in patients with non-smoking and PS〈2 was superior to patients with smoking and PS≥2. Non-smokers and PS〈2 were good predictors for survival with significant differences. The side effects were generally mild and consisted of rash and diarrhea. Conclusion EGFR-TKI is effective and well tolerated in elderly patients with advanced non-small-cell lung cancer. Non-smoking and PS 〈2 were independent factors of survival.

关 键 词：老年患者 癌 非小细胞肺:表皮生长因子受体 酪氨酸激酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]